We are live on ! Find out more
CNTX icon

Context Therapeutics
CNTX

39 hedge funds and large institutions have $45M invested in Context Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $43.7M → $45M (+$1.25M)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

3.11% less ownership

Funds ownership: 79.61% → 76.5% (-3.1%)

7% less funds holding

Funds holding: 42 → 39 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
39
Holders Change
-3
Holders Change %
-7.14%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LM
Luminus Management
Texas
+$236K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$77K
3
MCCA
Mill Creek Capital Advisors
Pennsylvania
+$75.2K
4
GS
GTS Securities
New York
+$31.8K
5
BOCH
Blue Owl Capital Holdings
New York
+$28.8K

Top Sellers

Rank Fund Capital Flow
1
ABG
Ally Bridge Group
New York
-$708K
2
AI
Allostery Investments
Connecticut
-$582K
3
WP
Woodline Partners
California
-$490K
4
SC
Shay Capital
New York
-$116K
5
AAA
Affinity Asset Advisors
New York
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
MB
1
MPM BioImpact
Massachusetts
$9.64M – – –
APM
2
Avidity Partners Management
Texas
$4.9M +$40 +55 +0%
DTC
3
Deep Track Capital
Connecticut
$4.86M – – –
NI
4
Nextech Invest
Switzerland
$4.86M – – –
BOCH
5
Blue Owl Capital Holdings
New York
$4.85M +$28.8K +40,000 +0.5%
GPP
6
Great Point Partners
Connecticut
$3.07M – – –
Franklin Resources
7
Franklin Resources
California
$2.62M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$2.2M +$77K +107,115 +3%
Blackstone Inc
9
Blackstone Inc
New York
$1.6M – – –
NCM
10
Nantahala Capital Management
Connecticut
$1.27M – – –
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.09M – – –
SCM
12
Sio Capital Management
New York
$879K +$9.55K +13,284 +1%
BlackRock
13
BlackRock
New York
$556K – – –
WP
14
Woodline Partners
California
$446K -$490K -681,000 -50%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$418K -$1.01K -1,409 -0.2%
AAA
16
Affinity Asset Advisors
New York
$339K -$103K -142,564 -22%
Renaissance Technologies
17
Renaissance Technologies
New York
$238K -$44.3K -61,570 -14%
ACM
18
ADAR1 Capital Management
Texas
$230K – – –
LM
19
Luminus Management
Texas
$215K +$236K +328,222 New
State Street
20
State Street
Massachusetts
$100K – – –
Walleye Capital
21
Walleye Capital
New York
$87K -$26K -36,174 -21%
HighTower Advisors
22
HighTower Advisors
Illinois
$82.5K – – –
Northern Trust
23
Northern Trust
Illinois
$74.4K – – –
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$70K -$48.6K -67,530 -39%
MCCA
25
Mill Creek Capital Advisors
Pennsylvania
$68.6K +$75.2K +104,631 New
1
2

CNTX Hedge Fund Activity: Q2 2025 in Review

39 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2025, worth a combined $45M — up 2.9% from $43.7M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CNTX and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Luminus Management, opening a new position worth an estimated $236K. The largest seller was Ally Bridge Group, exiting entirely with an estimated $708K sold.

  • 39 institutional investors held Context Therapeutics (CNTX) as of Q2 2025, down from 42 in Q1 2025.
  • Funds reported $45M of Context Therapeutics stock for Q2 2025, up 2.9% quarter-over-quarter.
  • 4 funds opened new Context Therapeutics positions in Q2 2025 and 7 closed out, a net change of -3 holders.
  • The largest Context Therapeutics buyer in Q2 2025 was Luminus Management, an estimated $236K added.
  • The largest Context Therapeutics seller in Q2 2025 was Ally Bridge Group, an estimated $708K sold.

Based on aggregated 13F filings for Q2 2025.